gutflix
GI learning, personalised

Summary

OVERALL SURVIVAL AND ASSOCIATION OF PRE-CHEMOTHERAPY ALBUMIN BILIRUBIN (ALBI) PROGNOSIS SCORE IN UNRESECTABLE CHOLANGIOCARCINOMA RECEIVED SYSTEMIC CHEMOTHERAPY

Asawin Soodcharoen

UEG Week Copenhagen 2023 | Poster

Hepatobiliary

October 15, 2023

A retrospective Thai cohort study found that lower ALBI prognostic scores were associated with significantly better overall survival in unresectable cholangiocarcinoma patients receiving systemic chemotherapy.

KEY POINTS

- 69 unresectable cholangiocarcinoma patients receiving systemic chemotherapy were studied retrospectively at a Thai medical center from 2012-2022, with most patients having intrahepatic type disease and ALBI group 2 scores.
- ALBI group 1 patients had significantly better median overall survival compared to ALBI group 2 patients (13.76 months versus 6.33 months, P <0.001).
- Overall median overall survival was 10.23 months and median progression-free survival was 5.77 months across the cohort.
- The authors suggest ALBI prognostic score may serve as a surrogate marker for predicting survival outcomes in cholangiocarcinoma patients receiving systemic chemotherapy.

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/d449a75e-743b-11ee-bcfc-0242ac140004

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.